ϟ
DOI: 10.1093/eurheartj/ehs253
¤ OpenAccess: Green
This work has “Green” OA status. This means it may cost money to access on the publisher landing page, but there is a free copy in an OA repository.
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
A. John Camm,Gregory Y.H. Lip,Raffaele De Caterina,Irene Savelieva,Dan Atar,Stefan H. Hohnloser,Gerhard Hindricks,Paulus Kirchhof,Jeroen J. Bax,Helmut Baumgartner,Claudio Ceconi,Veronica Dean,Christi Deaton,Robert Fagard,Christian Funck‐Brentano,David Hasdai,Arno W. Hoes,Juhani Knuuti,Philippe Kolh,Theresa A. McDonagh,Cyril Moulin,Bogdan A. Popescu,Željko Reiner,Udo Sechtem,Per Anton Sirnes,Michał Tendera,Adam Torbicki,Alec Vahanian,Stephan Windecker,Panos Vardas,Nawwar Al‐Attar,Ottavio Alfieri,Annalisa Angelini,Carina Blomström‐Lundqvist,Paolo Colonna,Johan De Sutter,Sabine Ernst,Andreas Goette,Bülent Görenek,Róbert Hatala,Hein Heidbüchel,Magnus Heldal,Steen Dalby Kristensen,Jean‐Yves Le Heuzey,Hercules E. Mavrakis,Lluı́s Mont,Pasquale Perrone Filardi,Piotr Ponikowski,Bernard Prendergast,Frans H. Rutten,Ulrich Schotten,Isabelle C. Van Gelder,Freek W.A. Verheugt
Medicine
Atrial fibrillation
Internal medicine
2012
ACCF
: American College of Cardiology Foundation
ACCP
: American College of Chest Physicians
ACS
: acute coronary syndrome
ACT
: Atrial arrhythmia Conversion Trial
ADONIS
: American–Australian–African trial with DronedarONe In atrial fibrillation or flutter for the maintenance of Sinus rhythm
AF
: atrial fibrillation
AHA
: American Heart Association
ANDROMEDA
: ANtiarrhythmic trial with DROnedarone in Moderate-to-severe congestive heart failure Evaluating morbidity DecreAse
APHRS
: Asia Pacific Heart Rhythm Society
aPTT
: activated partial thromboplastin time
ARB
: angiotensin-receptor blocker
ARISTOTLE
: Apixaban for Reduction In STroke and Other ThromboemboLic Events in atrial fibrillation
ATHENA
: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg b.i.d. for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter
ATRIA
: AnTicoagulation and Risk factors In Atrial fibrillation
AVERROES
: Apixaban VErsus acetylsalicylic acid (ASA) to Reduce the Rate Of Embolic Stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment
AVRO
: A prospective, randomized, double-blind, Active-controlled, superiority study of Vernakalant vs. amiodarone in Recent Onset atrial fibrillation
b.i.d
: bis in die (twice daily)
b.p.m.
: beats per minute
CABANA
: Catheter ABlation vs . ANtiarrhythmic drug therapy for Atrial fibrillation
CABG
: coronary artery bypass graft
CAP
: Continued Access to Protect AF
CHA2DS2-VASc
: Congestive heart failure or left ventricular dysfunction Hypertension, Age ≥75 (doubled), Diabetes, Stroke (doubled)-Vascular disease, Age 65–74, Sex category (female)
CHADS2
: Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke (doubled)
CI
: confidence interval
CRAFT
: Controlled Randomized Atrial Fibrillation Trial
CrCl
: creatinine clearance
DAFNE
: Dronedarone Atrial FibrillatioN study after Electrical cardioversion
DIONYSOS
: Randomized Double blind trIal to evaluate efficacy and safety of drOnedarone (400 mg b.i.d.) vs . amiodaroNe (600 mg q.d. for 28 daYS, then 200 mg qd thereafter) for at least 6 mOnths for the maintenance of Sinus rhythm in patients with atrial fibrillation
EAST
: Early treatment of Atrial fibrillation for Stroke prevention Trial
EHRA
: European Heart Rhythm Association
ECG
: electrocardiogram
EMA
: European Medicines Agency
ERATO
: Efficacy and safety of dRonedArone for The cOntrol of ventricular rate during atrial fibrillation
EURIDIS
: EURopean trial In atrial fibrillation or flutter patients receiving Dronedarone for the maIntenance of Sinus rhythm
FAST
: atrial Fibrillation catheter Ablation vs . Surgical ablation Treatment
FDA
: Food and Drug Administration
Flec-SL
: Flecainide Short-Long trial
HAS-BLED
: Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly
HF-PEF
: heart failure with preserved ejection fraction
HF-REF
: heart failure with reduced ejection fraction
HR
: hazard ratio
HRS
: Heart Rhythm Society
ICH
: intracranial haemorrhage
INR
: international normalized ratio
i.v.
: intravenous
J-RHYTHM
: Japanese RHYTHM management trial for atrial fibrillation
LAA
: left atrial appendage
LoE
: level of evidence
LVEF
: left ventricular ejection fraction
MANTRA-PAF
: Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation
NICE
: National Institute for Health and Clinical Excellence
NOAC
: novel oral anticoagulant
NSAID
: non-steroidal anti-inflammatory drug
NYHA
: New York Heart Association
OAC
: oral anticoagulant or oral anticoagulation
o.d.
: omni die (every day)
PALLAS
: Permanent Atrial fibriLLAtion outcome Study using dronedarone on top of standard therapy
PCI
: percutaneous coronary intervention
PREVAIL
: Prospective Randomized EVAluation of the LAA closure device In patients with atrial fibrillation v s. Long-term warfarin therapy
PROTECT AF
: WATCHMAN LAA system for embolic PROTECTion in patients with Atrial Fibrillation
PT
: prothrombin time
RAAFT
: Radio frequency Ablation Atrial Fibrillation Trial
RE-LY
: Randomized Evaluation of Long-term anticoagulant therapY with dabigatran etexilate
ROCKET-AF
: Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in atrial fibrillation
RRR
: relative risk reduction
TE
: thromboembolism
TIA
: transient ischaemic attack
t.i.d.
: ter in die (three times daily)
TOE
: transoesophageal echocardiogram
TTR
: time in therapeutic range
VKA
: vitamin K antagonist
Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on …
Loading...
- MLA
- APA
- Chicago
- IEEE
- Harvard
- BibTeX
Cite this:
Generate Citation
“2012 focused update of the ESC Guidelines for the management of atrial fibrillation” is a paper by A. John Camm Gregory Y.H. Lip Raffaele De Caterina Irene Savelieva Dan Atar Stefan H. Hohnloser Gerhard Hindricks Paulus Kirchhof Jeroen J. Bax Helmut Baumgartner Claudio Ceconi Veronica Dean Christi Deaton Robert Fagard Christian Funck‐Brentano David Hasdai Arno W. Hoes Juhani Knuuti Philippe Kolh Theresa A. McDonagh Cyril Moulin Bogdan A. Popescu Željko Reiner Udo Sechtem Per Anton Sirnes Michał Tendera Adam Torbicki Alec Vahanian Stephan Windecker Panos Vardas Nawwar Al‐Attar Ottavio Alfieri Annalisa Angelini Carina Blomström‐Lundqvist Paolo Colonna Johan De Sutter Sabine Ernst Andreas Goette Bülent Görenek Róbert Hatala Hein Heidbüchel Magnus Heldal Steen Dalby Kristensen Jean‐Yves Le Heuzey Hercules E. Mavrakis Lluı́s Mont Pasquale Perrone Filardi Piotr Ponikowski Bernard Prendergast Frans H. Rutten Ulrich Schotten Isabelle C. Van Gelder Freek W.A. Verheugt published in 2012. It has an Open Access status of “green”. You can read and download a PDF Full Text of this paper here.